Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia

Published:2013-04-04 Issue:14 Volume:121 Page:2618-2626
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bertoli Sarah¹,Bérard Emilie²³⁴,Huguet Françoise¹,Huynh Anne¹,Tavitian Suzanne¹,Vergez François⁵,Dobbelstein Sophie⁵,Dastugue Nicole⁵,Mansat-De Mas Véronique²⁵,Delabesse Eric²⁵,Duchayne Eliane⁵,Demur Cécile⁵,Sarry Audrey¹,Lauwers-Cances Valérie³,Laurent Guy¹²,Attal Michel¹²,Récher Christian¹²

Affiliation:

1. Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Toulouse, France;

2. Université Toulouse III Paul Sabatier, Toulouse, France;

3. Département d'Epidémiologie, Economie de la Santé et Santé Publique, Centre Hospitalier Universitaire de Toulouse, Toulouse, France;

4. Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1027, Epidémiologie et analyses en santé publique: Risques, maladies chroniques et handicaps, Faculté de médecine, Toulouse, France; and

5. Laboratoire d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Toulouse, France

Abstract

Key Points The prognostic impact of time from diagnosis to treatment in AML is offset by other factors such as age, secondary AML, or genetic abnormalities. Waiting a short period of time to characterize leukemias better and design adapted treatments at diagnosis seems possible.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/14/2618/1365182/2618.pdf

Reference28 articles.

1. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.;Marcucci;J Clin Oncol,2011

2. Therapeutic advances in acute myeloid leukemia.;Burnett;J Clin Oncol,2011

3. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.;Vardiman;Blood,2009

4. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.;Döhner;Blood,2010

5. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.;Schlenk;N Engl J Med,2008

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No impact of time from diagnosis to treatment on survival in newly diagnosed AML treated with venetoclax-based regimens;2024-02-02

2. No impact of time from diagnosis to treatment on survival in newly diagnosed AML treated with venetoclax-based regimens;2024-01-12

3. Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single‐center, retrospective study;European Journal of Haematology;2023-12-28

4. Improving long-term outcomes with intensive induction chemotherapy for patients with AML;Hematology;2023-12-08

5. Transforming Acute Myeloid Leukemia Treatment Through Next-Generation Sequencing: A Single-Center Experience;Cureus;2023-09-25